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Abstract Subarachnoid hemorrhage (SAH) is a serious clin-
ical condition where leakage of blood into the subarachnoid
space causes an acute rise in intracranial pressure and reduces
cerebral blood flow, which may lead to delayed cerebral is-
chemia and poor outcome. In experimental SAH, we have
previously shown that the outcome can be significantly im-
proved by early inhibition of the MAPK/ERK kinase/
extracellular signal-regulated kinase (MEK/ERK1/2) path-
way. The aim of this study was to apply mass spectrometry
to investigate the overall late effects of experimental SAH on
cerebrovascular protein expression. SAH was induced in rats
that were treated with theMEK1/2 inhibitor U0126 or vehicle.
Neurological outcome was assessed using a battery of behav-
ioral tests. Specific protein expression of large cerebral arteries
was analyzed quantitatively with high-throughput tandem
mass spectrometry. SAH resulted in a marked reduction of
neurological scores, which was counteracted by U0126 treat-
ment. Mass spectrometry analysis demonstrated regulation of
184 proteins after SAH, regulations that were in part
prevented by U0126 treatment. Network analysis identified
several protein networks including a strong structural network
centered around 14-3-3. Additionally, protein networks with
functions in mRNA metabolism and protein folding were
identified. Treatment with U0126 inhibited cerebral vessel
wall pERK1/2 expression and significantly improved out-
come of the rats. In conclusion, we show that SAH induces
a broad array of specific changes in the overall protein net-
works in cerebral artery smooth muscle cells and suggest that
this is essential for understanding the vascular pathophysiolo-
gy after SAH.
Keywords Animal model . SAH . Proteomics . Mass
spectrometry .MEK1/2 inhibition
Introduction
Subarachnoid hemorrhage (SAH) is a condition caused by
leakage of blood from a ruptured aneurysm into the subarach-
noid space which causes an acute rise in intracranial pressure
(ICP) and a diminished cerebral blood flow (CBF). During the
acute phase, there is a mortality rate of about 15%. After
cessation of the bleeding, patients might suffer from delayed
cerebral ischemia (DCI) with pathological constriction of ce-
rebral arteries, also known as cerebral vasospasm, in the days
following the insult. The DCI phase is progressive and can
result in infarction, neuronal loss, and poor outcome
(Edvinsson and Povlsen 2011). Experimental studies have in-
dicated plasticity of contractile cerebrovascular endothelin, 5-
hydroxytryptamine 1B (5-HT1B), angiotensin AT1, and throm-
boxane A2 receptors in the ischemic process (Ansar and
Edvinsson 2008; Ansar et al. 2010; Hansen-Schwartz et al.
2003). These receptor alterations are associated with reduced
regional CBF and poor outcome (Ansari 2007).
Proteomics, blended from protein and genome, is large-
scale studies of proteins. The possibility to obtain a picture
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of the total protein expression at a given time in a given tissue
has greatly improved during the last 10 years with the acces-
sibility of high-throughput mass spectrometry methods
(Cottrell 2011). With this technology, thousands of proteins
can be identified and quantified in a single study, which has
made it possible to investigate, e.g., effects of diseases and
treatments on protein expression in various tissues.
In experimental SAH in rats, we have previously shown
that the outcome can be significantly improved by inhibition
of the MAPK/ERK kinase/extracellular signal-regulated ki-
nase (MEK-ERK) pathway days after the insult (Larsen
et al. 2011). We reported that the MEK1/2 inhibitor U0126
prevents upregulation of the contractile receptors ETB and 5-
HT1B, and reduces vascular thickening evident 2 days post-
SAH (Edvinsson and Povlsen 2011; Parker et al. 2013).
Moreover, analysis of acute (0.5–1 h post insult) SAH
in vivo events has shown SAH-induced regulation of focal
adhesion molecules and actin cytoskeleton dynamics, and in
addition a central role of activation of ERK1/2 (Parker et al.
2013).s
The detailed analysis of acute SAH events by Parker et al.
(Parker et al. 2013) revealed the proteomic changes immedi-
ately associated with the insult. However, no large-scale pro-
teomic analysis of the alterations in proteins 48 h after SAH, a
time-point more closely related to the development of DCI,
has yet to be performed. Hence, the aim of this study was to
apply high-throughput quantitative tandemmass spectrometry
to establish later effects of experimental SAH on the protein
expression in the cerebral vessels. Moreover, because the in-
hibition of MEK-ERK1/2 activation has a prophylactic effect
in later cerebrovascular changes after SAH, we investigated
the effects of U0126 on the SAH-induced proteomic changes
(Larsen et al. 2011).
Experimental Procedures
All animal procedures were carried out strictly within national
laws and guidelines and were approved by the Danish Animal
Experimentation Inspectorate (license no. 2011/561-2025).
Rat Subarachnoid Hemorrhage Model
SAH was induced as described by Prunell et al. (2002). Male
Sprague-Dawley rats 350–400 g (Taconic, Denmark) were
anesthetized using 3.5% isoflurane (Baxter A/S, Denmark)
in atmospheric air and O2 (70:30). Anesthesia was maintained
by intubation and artificial ventilation of 1–2% isoflurane in
N2O/O2 (70:30) during the surgical procedure. Respiration
was monitored by regularly withdrawing blood samples to a
blood gas analyzer (Radiometer, Denmark). A temperature
probe was rectally inserted to record the body temperature,
which was maintained at 37 °C by a heating pad. ICP was
measured via a catheter inserted into the basal cisterna via a
hole in the atlanto-occipital membrane. The catheter was con-
nected to a pressure transducer and the signal was recorded in
the software LabChart via a PowerLab (both from AD
Instruments, UK). Mean arterial blood pressure (MABP)
was measured via a tail artery catheter connected to a pressure
transducer and recorded in LabChart. Cortical CBF was mea-
sured with a laser-Doppler fiber optic probe placed directly on
the dura mater on the surface of the brain via a hole drilled
through the skull, 4 mm anterior from the bregma and 3mm to
the right of the midline, without perforation of the dura. ICP,
MABP, and CBF were measured in real time with recordings
commencing approximately 30 min before SAH and continu-
ing until 1 h after SAH.
A 27G blunt cannula was stereotactically placed 6.5 mm
anterior to the bregma in the midline at an angle of 30° to the
vertical plane, it was lowered until it met the base of the scull,
and then retracted 1 mm placing the tip of the needle just in
front of the chiasma opticum. Rats equilibrated 30 min before
300 μl of blood was withdrawn from the tail catheter and
injected manually into the prechiasmatic cisterna at a pressure
equal to the MABP (80–100 mmHg). Rats were maintained
under anesthesia for another 60 min in order to recover. The
ICP catheter was cut and sealed with a removable plug 2 cm
from the tip. The tail catheter, the needle, and the laser-
Doppler probe were removed and incisions closed.
Carprofen (4 mg/kg; Pfizer, Denmark) against pain was ad-
ministered subcutaneous as well as 15 ml saline for hydration.
Rats were then revitalized and extubated. Sham-operated rats
went through the same procedure, with the exception that no
blood was injected intracisternally.
Experimental Groups
A total of 40 rats underwent surgery for the neurological eval-
uation and mass spectrometric analysis and 18 rats underwent
surgery for Western blot validation. The mass spectrometry
was conducted in duplicates and each sample consisted of
tissue from four to five rats. These rats also went through
neurological assessment, meaning that there were 9–10 bio-
logical replicates in each group for neurological evaluation.
Western blot was carried out in technical duplicates with four
to six biological replicates and each sample consisted of pro-
tein purified from one rat. In order to assess whether MEK-
ERK1/2 activity was involved in the vascular response in the
first 2 days post-SAH, thus, we compared animals treated with
either U0126 (1,4-diamino-2,3-dicyano-1,4-bis [2-
aminophenylthio] butadiene) (Duncia et al. 1998) or vehicle
(DMSO) at 6, 12, 24, and 36 h post-SAH with sham-operated
rats that received neither U0126 nor vehicle.
Animals were randomly selected for treatment with either
U0126 or vehicle. U0126 was given as 0.05 ml/kg body
weight of a 10−5 M solution of U0126 ethanolate (Sigma-
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Aldrich, MO, USA) in isotonic saline with 0.1% DMSO,
yielding a final dose of 0.22 μg /kg body weight. Vehicle
consisted of 0.1% DMSO in isotonic saline. Treatment was
administered intracisternal through the ICP catheter placed
with the tip in the basal cistern.
At 48 h post-surgery, all rats were anesthetized using CO2
and decapitated. In a dissection microscope, the middle cere-
bral arteries (MCAs), the circle ofWillis, and the basilar artery
were carefully dissected free of brain tissue and cleaned of
connective tissue and blood, and stored at −80 °C.
Neurological Function
Neurological evaluations (rotating pole test and spontaneous
behavior observations) were performed by personnel blinded
with regard to experimental groups. Tests and observations
were performed in a silent room with as few visual disturbing
elements as possible.
Rotating Pole Test
Gross sensorimotor function of animals was evaluated by test-
ing their balance and coordination of movements on a rotating
pole (45 mm in diameter and 150 cm in length), which was
either steady or rotating at different speeds (3 or 10 rpm)
(Ohlsson and Johansson 1995). A cage where the floor was
covered with bedding material from the home cage of the rat
was placed at the end of the pole opposite from the rat to serve
as a positive reinforcement for the rat to traverse the pole, and
the ability of the rats to traverse the pole was monitored. The
performance of the rat was scored according to the following
definitions: Score 1, the animal is unable to sit on the pole and
falls off immediately. Score 2, the animal has severe difficul-
ties to stay on the pole, but manages to balance for a while and
move less than 30 cm on the pole. Score 3, the animal em-
braces the pole with paws while crossing, but manages to
move more than 30 cm. Score 4, the animal manages to tra-
verse the pole and reach the platform but moves with the body
close to the pole, embraces the pole, or jumps with hind legs.
Score 5, the animal traverse the pole with normal posture but
displays one or several of the following deficits: foot slips
(less than 10), slightly disturbed pattern of movement, stops
along the pole, and has difficulty staying on the pole while
standing still. Score 6, the animal traverses the pole perfectly
with 0–2 ft slips and no stops. Results were analyzedwith one-
way ANOVA with Dunn’s multiple comparison post-test.
Significance level was set to p < 0.05.
Spontaneous Behavior
Spontaneous activity of the rats was quantified by placing
the rats individually in a test cage with fresh bedding and
nesting material for 20 min. An observer equipped with a
timer recorded all time intervals spent moving around in
the cage (locomotion), sitting or lying in the same place
(no movement), rearing, or grooming. Results were ana-
lyzed with one-way ANOVA and Newman-Keuls multiple
comparison post-test. Significance level was set to
p < 0.05.
Protein Purification
Tissue from cerebral arteries was dounce homogenized in ice-
cold 0.1 M Na2CO3 containing 1 tablet PhosSTOP phospha-
tase inhibitor cocktail (Roche, France) per 10 ml and 1 ml
P8340 protease inhibitor (Sigma-Aldrich, MO, USA) per
20 ml, and then tip-probe sonicated 2 × 20 s on ice.
Homogenates were ultra-centrifuged at 150,000×g for 1.5 h.
Pellets (membrane fractions) were resuspended in 6 M
urea/2 M thiourea. Supernatants (soluble fractions) were pre-
cipitated using 20% trichloroacetic acid, and pellets from this
precipitation were resuspended in 6 M urea/2 M thiourea.
Samples were reduced in 10 mM dithiothreitol, then alkylated
using 20 mM iodoacetamide. Lysyl-endopeptidase (Wako,
Osaka, Japan) was added for 3 h, and then samples were
diluted 6-fold in 50 mM triethyl ammonium bicarbonate.
Trypsin (Promega, WI, USA) was added at a ratio of 1:40
(w/w) and left for 18 h to digest. Digests were acidified by
addition of formic acid to a final concentration of 2% and the
protein contents of samples were quantified using amino acid
composition analysis. Equal amounts of protein from each
sample were iTRAQ four-plex labeled according to the man-
ufacturer’s instructions (AB Sciex, MA, USA), equal labeling
was confirmed on a Bruker UltraFlex MALDI MS/MS instru-
ment (Bruker,MA, USA), and samples were combined to give
equal reporter intensity.
Combined peptide samples were cleaned up on a home-
made R3 column and then dried down for hydrophilic inter-
action liquid chromatography (HILIC). Peptide samples were
resuspended in 90% acetonitrile (ACN)/0.1% trifluoroacedic
acid (TFA) and loaded onto a micro-HILIC HPLC chroma-
tography system. The HILIC resin was TSK-gel Amide 80
(Tosoh Bioscience, Japan). Samples were separated over a
gradient of 90–60% organic solvent over 30 min, then 60–
0% over 15 min. Fractions were collected every minute at
absorbances over 500 mAU and every 5 min otherwise. All
fractions were lyophilized.
Mass Spectrometry
Dry peptide fractions were resuspended in 0.1% FA and load-
ed onto a Thermo Easy-LC system. Peptides were eluted
using a 0–34% organic gradient over 70 min, then 34–100%
over 20 min. All LC-MS runs were performed on columns
with a 75-μm inner diameter, packed with C18 material (Dr.
Maisch, Ammerbuch-Entringen, Germany). Mass
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spectrometry (MS) was performed using higher-energy colli-
sional dissociation (HCD) fragmentation on a Thermo LTQ
Velos (Thermo Fisher Scientific, Germany). Quantification
was performed on reporter tags at m/z 114, 115, 116, and
117. MS was performed with the following settings: A full
MS scan in the mass area of 400–1800 Da was performed in
the Orbitrap with a resolution of 30,000 FWHM and a target
value of 1 × 106 ions. For each full scan, the seven most
intense ions (>+1 charge state) were selected for HCD and
detected at a resolution of 7500 FWHM. HCD was performed
with the following settings: threshold for ion selection was
20,000, the target value of ions used for HCD was 1 × 105,
and activation time was 1 ms, the isolation window was
2.5 Da, and the normalized collision energy was 48.
Analysis of Mass Spectrometry Data
Data was searched using Thermo Proteome Discoverer (ver-
sion 1.3.0.339) and Mascot (v2.2, Matrix Science Ltd., UK)
allowing for variable methionine oxidation. Enzyme speci-
ficity was set for trypsin, with two missed cleavages
allowed. Precursor mass tolerance was 10 ppm and fragment
mass tolerance was set to 0.05 Da. iTRAQ labeling was also
set as a variable modification in order to detect lysine mod-
ification, while cysteine carbamidomethylation was set as a
fixed modification. Data were searched against a Swiss-prot
rodent database (UniProtKB/Swiss-Prot 2012_10). Data
were filtered to 1% peptide FDR with a decoy approach
using percolator and filtered to remove Mascot scores less
than 18, as previously described (Engholm-Keller et al.
2012). Data was exported from Proteome Discoverer and
manually normalized to protein median values across an
entire labeling experiment to correct for protein abundance
variation. Protein and peptide regulation was defined based
on the log2-transformed iTRAQ ratios and considered regu-
lated when exceeding 2 standard deviations from the median
ratio for a given tag. Proteins were classified according to
their molecular function using the PANTHER database
(www.panther.db) and network analysis was performed
using STRING, version 9 (www.string.db) (Szklarczyk
et al. 2011).
Western Blot
Each purified protein sample was prepared fromMCAs, circle
of Willis, and the basilar artery from one animal. Samples
were sonicated in RIPA buffer (50 mM Tris-HCl buffer
pH 7.5, 150 mM NaCl, 1 mM EDTA pH 8.0, 1% NP-40,
0.1% SDS, 0.5% Triton X-100, 50 mM β-glycerolphosphate,
0.1% deoxycholic acid) with 1 tablet Complete Protease
Inhibitor Cocktail (Roche, France) per 50 ml, and 1 tablet
PhosSTOP Phosphatase Inhibitor Cocktail (Roche, France)
per 10 ml RIPA.
Protein concentrations were determined with a spectro-
photometer (Infinite M200, TECAN, Switzerland).
Purified protein samples were run on a 4–20% precast
SDS gel (Expedeon Inc., USA) and blotted onto a nitrocel-
lulose membrane (GE Healthcare, USA). Membranes were
blocked for 1 h in 5% bovine serum albumin (BSA) in Tris-
buffered saline (50 mM Tris, 150 mM NaCl, pH 7.6) with
0.05% (v/v) Tween-20 (TBS-T) at room temperature and
incubated over night at 4 °C with primary antibodies dilut-
ed in 5% BSA TBS-T (Supplementary Table S1). After a
5 min wash, the membranes were incubated 1 h at room
temperature with secondary antibody diluted in 5% BSA
TBS-T (Supplementary Table S1), washed five times 5 min
in TBS-T and developed using ECL Select (GE Healthcare,
USA) and a LAS4000 (Fujifilm, Japan). Blots were quan-
tified with Image Gauge V3.2 (Fujifilm, Japan) and inten-
sities for band representing 14-3-3 were normalized to in-
tensities for bands representing SM22 which was used as
loading control. Normalized intensities for the U0126-
treatment and DMSO-treatment groups, respectively, were
compared to normalized intensities for the sham-surgery
group using one-way ANOVA and Newman-Keuls test
for multiple comparison significance; the level was set to
p < 0.05.
Immunohistochemistry
Immunohistochemical staining was performed on cere-
bral vessel segments (from three rats of the sham group,
SAH with vehicle or U0126 group). The tissues were
embedded in Tissue-Tek®, frozen on dry ice, and stored
at −80 °C until further processing. They were sectioned
(10 μm) on a cryostat (Leica, Denmark) and mounted on
microscope slides (SuperFrost®, Menzel, Germany). The
sections were fixed for 20 min using Stefanini’s fixative
(2% paraformaldehyde and 0.2% picric acid in phosphate
buffer, pH 7.2) and permeabilized in phosphate-buffered
saline (PBS) containing 0.25% Triton X-100 (T-PBS). To
prevent nonspecific staining, sections were blocked with
2% donkey serum and 1% BSA in T-PBS for 1 h.
Samples were incubated at 4 °C overnight with primary
anti-pERK1/2 antibody (1:250, alx-210-506a, Alexis
Biochemicals, Nottingham, UK) diluted in T-PBS. The
following day, the slides were rinsed three times in T-
PBS and incubated with secondary donkey anti-sheep
DyLight™ 488 antibody (1:200, 713-485-003, Jackson
ImmunoResearch, UK) or secondary donkey anti-mouse
FITC (1:100, Jackson Immunoresearch Laboratories) for
1 h in room temperature followed by three washes in T-
PBS before mount ing with Vectashie ld (Vector
Laboratories, Burlingame, CA, USA). Primary antibody
was omitted as a negative control.
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Results
Physiological Parameters
Two groups of animals were subjected to SAH and then treat-
ed with either U0126 or vehicle at 6, 12, 24, and 36 h post-
SAH. A third group of animals were subjected to sham sur-
gery and received neither U0126 nor vehicle (Supplementary
Fig. S1).
Measurements of the physiological parameters during SAH
surgery showed that ICP reached values of 10–20 mmHg
above MABP (80–100 mmHg) and cortical CBF was lowered
to 75% compared to flow before insult, and did not return to
baseline for a minimum of 10 min. These results
(Supplementary Table S2) are comparable with values in our
previous study (Povlsen et al. 2013) and values did not differ
between groups. The mortality rate after 48 h was 16%.
Neurological Functions
Neurological functionwas assessed using the rotating pole test
and standardized observations of spontaneous behavior by
trained personnel blinded to the experimental groups. The
ability of the rats to traverse a rotating pole at either no rota-
tion, at 3, or 10 rpm was significantly decreased by induction
of SAH. This reduction was restored byU0126 treatment (Fig.
1). The administration of U0126 in SAH animals was well
tolerated and did not modify ICP, CBF, or MABP differently
as compared to the DMSO-treated SAH group (Larsen et al.
2011).
Observations on time spend with no movements, locomo-
tion, rearing, and grooming were recorded using a standard-
ized protocol. It was found that induction of SAH worsened
the neurological function of rats as seen by a significant
change in time spent with no movement and locomotion
(Fig. 2). This change was significantly neutralized by U0126
treatment. In addition, SAH markedly decreased time spent
with rearing (p < 0.001) and increased the time of grooming;
these effects were partly restored after U0126 treatment
(p < 0.05) (Fig. 2).
In conclusion, inhibition of vessel wall pERK1/2 (U0126
treatment) of rats subjected to SAH improved the neurology
functional parameters as compared to treatment with vehicle.
Proteome Analysis in SAH in the Absence or Presence
of MEK1/2 Inhibition
In order to obtain an overview of protein expression in cere-
bral vessels after induction of SAH and to assess the effect of
treatment with the MEK1/2 inhibitor U0126, tandem mass
spectrometry with isobaric tags for relative and absolute quan-
titation (iTRAQ) was used to generate quantitative total
proteomes for the three groups of animals (sham, vehicle-,
or U0126 treatment) (Ong and Mann 2005; Ross et al. 2004;
Steen and Mann 2004).
The analysis of the cerebral vessel proteome was per-
formed in duplicates, each sample containing a pool of cere-
bral vessels (MCAs, circle of Willis, and basilar artery) from
four to five animals dissected 48 h after rats were subjected to
either SAH (and treated with either U0126 or vehicle) or sham
surgery. Pilot studies showed no effect of vehicle per se or of
U0126 to non-SAH sham surgery animals (data not shown).
The cerebral artery samples were iTRAQ labeled as fol-
lows: U0126-treated groups were labeled with iTRAQ 114,
vehicle-treated groups were labeled with iTRAQ 115, and
sham groups were labeled with iTRAQ 116. Tandem mass
spectrometry was performed on a 1:1:1 mixture of all three
groups simultaneously. Protein levels in the different groups
were determined based on the intensities of the tags compared
with sham. Because this was an overall screening proteome
study, the results include all identified proteins in the groups.
Core Results A total of 2677 proteins were identified. The
effect of SAH on protein expression in cerebral vessels (without
any contamination of brain tissue) was assessed by comparing
the regulated proteins of rats subjected to SAH and treated with
vehicle with the regulated proteins of rats subjected to sham
surgery (this group did not differ in expression from sham sur-
gery with or without U0126; data not shown).When examining
the SAH vehicle group, we identified 171 upregulated proteins
and 79 downregulated proteins compared with sham. The ten
most upregulated and downregulated proteins are shown in
Table 1A and B. Using the PANTHER database, we sorted
the proteins based on their molecular function.1 Of the 171
upregulated proteins, 159 were recognized in the database with
a total of 171 hits.2 Of the allocated proteins, 39.9% (68 pro-
teins) were involved in catalytic activity, 30.4% (52 proteins) in
binding of either nucleic acids, proteins, or calcium ions, 17%
(29 proteins) in structural activity, 1.8% (3 proteins) in enzyme
regulator activity, 2.9% (5 proteins) in transcription factor ac-
tivity, 3.5% (6 proteins) in receptor activity, 12.3% (4 proteins)
in translation, and 2.3% (4 proteins) have transporter functions
(Supplementary Fig. S2).
Of the 79 downregulated proteins, 72 were found in the
PANTHER database and gave 82 hits. Of these proteins,
30.5% (25 proteins) were involved in binding,3 29.3% (24
proteins) in catalytic activity, 15.3% (11 proteins) in structural
activity, 9.8% (8 proteins) have transporter functions, 7.3% (6
1 One protein can have several functions and it might therefore appear in more
than one group. Additionally, the database did not allocate all the identified
proteins.
2 Hits are defined as the total number of molecular functions assigned for the
recognized proteins.
3 In the PANTHER classification system, binding is defined as calcium ion
binding, calcium-dependent phospholipid binding, chromatin binding, lipid
binding, nucleic acid binding, and protein binding (www.pantherdb.org).
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proteins) are involved in receptor activity, 6.1% (5 proteins) in
enzyme regulator activity, 2.4% (2 proteins) in translation, and
1.2% (1 protein) in transcription factor activity (Supplementary
Fig. S2). This demonstrates that the response to SAH in the
major cerebral arteries involves both up- and downregulation of
mainly proteins with binding, catalytic, and structural func-
tions. The stronger of the two responses seems to be upregula-
tion of proteins rather than downregulation. Importantly, we
Fig. 2 Behavioral observations
of rats treated with U0126 or
vehicle post-SAH. Rats were
observed for 20 min and the
duration of their spontaneous
activities was quantified. Data are
mean time spent on each
activity ± S.E.M.; n = 8–9.
Compared with sham-operated
animals, rats that underwent SAH
performed significantly poorer
with no movement (a),
locomotion (b), rearing (c), and
grooming (d). Animals that
underwent SAH and were treated
with U0126 performed
significantly better than animals
treated with vehicle with no
movement (a) and locomotion
(b). Data were analyzed with one-
way ANOVA and Newman-
Keuls post-test for multiple
comparison: * = p < 0.05,
** = p < 0.01, *** = p < 0.001
Fig. 1 Neurological assessment of rats treated with U0126 or DMSO
post-SAH. Rats were tested for their ability to traverse a 1.5-m pole
with either no rotation, 3, or 10 rpm. Each data point is the score of one
rat; n = 7–9. Horizontal lines are median score. Compared with sham-
operated animals, rats that underwent SAH performed significantly
poorer at no rotation (a) and 3 rpm (b). At 10 rpm (c), there was no
significant difference between sham and SAH. Animals that underwent
SAH and were treated with U0126 performed significantly better than
animals treated with vehicle at no rotation (a). Data were analyzed with
one-way ANOVA and Dunn’s post-test: * = p < 0.05, ** = p < 0.01
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show that a wide range of proteins were regulated after SAH,
hence targeting a single protein is not a viable way to counteract
the detrimental effects of SAH.
The Effect of MEK1/2 Inhibition
The first part was verification in the circle of Willis arteries that
treatment with U0126 had efficacy per se. This has been done
in aWestern blot quantitative study before using the same SAH
method (Ansar and Edvinsson 2008). Here, we confirm this
effect using immunohistochemistry. We verified that SAH in-
duced enhanced expression of pERK1/2 in the cerebral vascu-
lar smooth muscle cells (VSMC), while this was unaltered in
the U0126-treated vessels (Fig. 3). The effect of MEK1/2 inhi-
bition on SAH-induced changes in protein expression was
assessed in a two-step procedure where the first step was to
compare SAH animals treated with U0126 with sham animals.
Hereby, 104 proteins were identified as upregulated and 183
proteins were found to be downregulated, which indicates that
MEK1/2 inhibition affects the SAH-induced expressional
changes in cerebral vessels. The next step in order to identify
downstream targets of MEK1/2 was to search for proteins that
fulfilled one of the following criteria: 1, the protein is
upregulated in vehicle-treated animals (as compared with sham
animals) and either downregulated or not affected in U0126-
treated animals (as compared with sham animals). 2, The pro-
tein is downregulated in vehicle-treated animals (as compared
with sham animals) and either upregulated or not affected in
U0126-treated animals (as comparedwith sham animals). A list
of 133 proteins (Table 2) was identified using criteria 1. This
group (hereafter denoted group 1) represents proteins with an
SAH-induced expressional increase that does not persist after
MEK1/2 inhibition. A list of 51 proteins (Table 3) was identi-
fied based on criteria 2. This group (hereafter denoted group 2)
represents proteins with an SAH-induced expressional decrease
that does not persist after MEK1/2 inhibition.
Network analysis of group 1 proteins was performed using
the STRING database for protein interactions4 (Figs. 3 and 4).
Of the 133 identified proteins, the database recognized 107 and
constructed a network of protein interactions (Fig. 4). The anal-
ysis showed that many of the proteins were regulated through
each other either directly or indirectly. In particular, the analysis
revealed a network of proteins with structural functions which
includes actinin and vinculin. Actinin is a structural protein and
it is involved in cytoskeletal stability. Vinculin is a protein in-
volved in focal adhesions via interaction with actin and other
structural proteins (Sun et al. 2008). Another group of highly
interconnected proteins includes three isoforms of the adaptor
protein 14-3-3 (14-3-3 protein zeta/delta, gamma, and epsilon)
4 STRING did not allocate interactions to all identified proteins. The network
analyses only contain proteins where interactions could be allocated.
Table 1 The ten most
upregulated and downregulated
proteins after SAH. The table
shows proteins that are regulated
after SAH and the level of
regulation is expressed as log2 of
the iTRAQ ratios. (A) The ten
most upregulated proteins after
SAH when compared with sham.
(B) The ten most downregulated
proteins after SAH when
compared with sham
Accession number Protein name Log2
A: The ten most upregulated proteins after SAH
P50116 Protein S100-A9 3.96
9JJ54 Heterogeneous nuclear ribonucleoprotein D0 3.84
Q9Z1Z3 Epsin-2 3.78
Q925G0 Putative RNA-binding protein 3 3.74
B3EWD2 Hemoglobin subunit beta 3.70
Q8VC52 RNA-binding protein with multiple splicing 2 3.70
Q9DBR1 5′-3′ Exoribonuclease 2 3.58
Q63083 Nucleobindin-1 3.58
P11348 Dihydropteridine reductase 3.57
P63281 SUMO-conjugating enzyme UBC9 3.55
B: The ten most downregulated proteins after SAH
Q62715 Neutrophil antibiotic peptide NP-2 −5.38
P04764 Alpha-enolase −5.38
D3ZLY9 Histone H2B type 1-H −4.82
P05811 Alpha-crystallin B chain −4.47
Q5RKG9 Eukaryotic translation initiation factor 4B −4.09
Q6LED0 Histone H3.1 −3.96
P04646 60S ribosomal protein L35a −3.85
P08081 Clathrin light chain A −3.75
P08009 Glutathione S-transferase Yb-3 −3.64
Q9JM53 Apoptosis-inducing factor 1, mitochondrial −3.42
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(Fig. 6). The 14-3-3 adaptor protein has a large number of
reported interaction partners and roles in apoptosis, cell cycle,
migration, and differentiation (Mhawech 2005). Networks of
proteins involved in translation, mRNA processing, and protein
folding such as translational initiation factor 3 subunits,
Polyadenylate-binding protein 1 and ribosomal protein subunits
S40 isoforms were also identified. Furthermore, a network of
proteins responsible for vesicle transport and formation includ-
ing epsin and phosphatidylinositol-binding clathrin assembly
protein and a network of reductases were found including qui-
none reductase 1 and glutathione reductase.
When performing a network analysis of those proteins whose
SAH-induced downregulation disappeared after U0126 treat-
ment (group 2 proteins), two networks were suggested (Fig. 5).
One network included six proteins involved in metabolism such
as ATP synthase and cytocrome C synthase. The other network
contained three proteins involved in immune responses.
Validation of Specific Proteins and Their Regulation
We chose to validate proteins from the strong networks of the
proteins that were found upregulated after SAH and normal-
ized by MEK1/2 inhibition (group 1 proteins). We studied the
expression of 14-3-3 protein in animals subjected to sham
surgery or SAH with or without U0126 treatment with
Western blot. This protein was detectable in all three groups,
supporting that they are indeed expressed in cerebral vessels.
Furthermore, the adaptor protein 14-3-3 showed regulation
(one-way ANOVA, p = 0.05), more specifically 14-3-3 tends
to be upregulated after SAH, whereas treatment with U0126
did not affect this upregulation (Fig. 6).
Discussion
This study is the first to show on an overall proteomic level the
expressional changes that occur in large cerebral arteries at
48 h post-SAH and to address how these proteomic changes
are affected by treatment with a MEK1/2 inhibitor.
Localization studies demonstrated this to occur early after
SAH and to maintain elevated levels in the VSMCs (Ansar
and Edvinsson 2008). It is worth noting that much of previous
work to find novel ways of therapy in order to reduce cerebral
vasospasm and the development of late cerebral ischemia after
SAH have centered on single molecular approaches. Our
study clearly reveals that a large number of proteins show
differential expression in the cerebral vessel walls following
an experimental SAH and this supports our vision that therapy
must be directed towards a common signal transductionmech-
anism (Edvinsson and Povlsen 2011).
We have shown that the MEK/ERK pathway is activated in
cerebral ischemia and that the activation results in enhanced
expression of contractile cerebrovascular receptors such as
endothelin type B, 5-hydroxytryptamie type 1B, angiotension
II type AT1, and thromboxane receptors in the cerebral arteries
associated with the ischemic region. Most interesting the spe-
cific inhibitor U0126 not only prevents this receptor upregu-
lation but importantly has a beneficial effect on the outcome
after experimental subarachnoid hemorrhage in rats (Larsen
et al. 2011). Compared to rats treated with vehicle, the U0126-
treated rats perform better on a rotating pole test and showed
increased spontaneous activity, rearing, grooming, and loco-
motion as compared to vehicle-treated animals. These find-
ings are in line with and extend previous work (Edvinsson and
Povlsen 2011; Larsen et al. 2011; Parker et al. 2013). The
present study thus adds to the evidence pointing to the
MEK/ERK pathway as a major player in SAH pathophysiol-
ogy and outcome.
The proteome of major cerebral arteries after SAH revealed
that pathways linked to structural modifications of the cerebral
blood vessel wall, mainly the VSMCs, are highly regulated
after SAH. In addition, we found that proteins involved in
binding of nucleic acids, proteins, or calcium ions, and in
catalytic activity are highly regulated.
Fig. 3 pERK immunohistochemistry on middle cerebral artery. a The
image showsMCA of a sham-operated animal. No pERK is visible in the
vessel. b The image demonstrates specific pERK immunoreactivity in the
vessel after induction of SAH. c Treatment with U0126 attenuates the
pERK immunoreactivity in the vessel
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Table 2 Proteins that show a
SAH-induced upregulation which
does not persist after MEK
inhibition. The list shows proteins
that fulfilled the following
criteria: the protein is upregulated
in vehicle-treated animals (as
comparedwith sham animals) and
either downregulated or not
affected in U0126-treated animals
(as compared with sham animals).
Regulation is expressed as log2 of
the iTRAQ ratios. This group of
133 proteins is referred to as
group 1 and represents proteins
with an SAH-induced
expressional increase that does
not persist after MEK1/2
inhibition
Accession
number
Protein name Log2
Q9JJ54 Heterogeneous nuclear ribonucleoprotein D0 3.84
Q4FZY0 EF-hand domain-containing protein D2 3.78
Q9Z1Z3 Epsin-2 3.78
Q925G0 Putative RNA-binding protein 3 3.74
B3EWD2 Hemoglobin subunit beta 3.70
B5DFF2 RNA-binding protein with multiple splicing 2 3.70
Q9DBR1 5′-3′ Exoribonuclease 2 3.58
Q63083 Nucleobindin-1 3.58
P11348 Dihydropteridine reductase 3.57
P63281 SUMO-conjugating enzyme UBC9 3.55
Q8BQ30 Phostensin 3.54
Q6P686 Osteoclast-stimulating factor 1 3.52
Q63797 Proteasome activator complex subunit 1 3.46
Q8K297 Procollagen galactosyltransferase 1 3.45
Q4KM73 UMP-CMP kinase 3.41
Q924S5 Lon protease homolog, mitochondrial 3.38
Q9QX47 Protein SON 3.34
Q5U318 Astrocytic phosphoprotein PEA-15 3.33
P61149 Fibroblast growth factor 1 3.28
Q5BJK8 Golgi integral membrane protein 4 3.28
O08586 Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 3.25
D3ZQN7 Laminin subunit beta-1 3.22
P62815 V-type proton ATPase subunit B, brain isoform 3.22
Q9DBZ5 Eukaryotic translation initiation factor 3 subunit K 3.16
P61972 Nuclear transport factor 2 3.15
Q4FZY0 EF-hand domain-containing protein D2 3.13
Q6PEV3 WAS/WASL-interacting protein family member 2 3.11
P63326 40S ribosomal protein S10 3.10
Q6AY09 Heterogeneous nuclear ribonucleoprotein H2 3.03
Q63663 Interferon-induced guanylate-binding protein 2 3.02
P52303 AP-1 complex subunit beta-1 2.97
P60868 40S ribosomal protein S20 2.97
Q64611 Cysteine sulfinic acid decarboxylase 2.90
P51583 Multifunctional protein ADE2 2.89
Q63871 DNA-directed RNA polymerases I, II, and III subunit RPABC4 2.89
Q5U211 Sorting nexin-3 2.87
P27615 Lysosome membrane protein 2 2.86
Q4KM65 Cleavage and polyadenylation specificity factor subunit 6 2.86
Q62865 cGMP-inhibited 3′,5′-cyclic phosphodiesterase A 2.85
P55260 Annexin A4 2.84
Q8R361 Rab11 family-interacting protein 5 2.81
P97379 Ras GTPase-activating protein-binding protein 2 2.81
Q66H20 Polypyrimidine tract-binding protein 2 2.78
Q6AXS3 Protein DEK 2.72
P36876 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha
isoform
2.72
B5DFC8 Eukaryotic translation initiation factor 3 subunit C 2.72
Q9QWE9 Gamma-glutamyltransferase 5 2.71
Q63433 Serine/threonine-protein kinase N1 2.70
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Table 2 (continued)
Accession
number
Protein name Log2
Q4KM74 Vesicle-trafficking protein SEC22b 2.69
Q5U2T8 Corepressor interacting with RBPJ 1 2.64
Q9WVA3 Mitotic checkpoint protein BUB3 2.61
Q8CIE6 Coatomer subunit alpha 2.59
G3V9C7 Histone H2B type 1-K 2.57
Q9Z340 Partitioning defective 3 homolog 2.55
P97633 Casein kinase I isoform alpha 2.47
P41499 Tyrosine-protein phosphatase non-receptor type 11 2.46
P60711 Actin, cytoplasmic 1 2.45
Q9R1Z8 Vinexin 2.45
Q63560 Microtubule-associated protein 6 2.42
Q27W02 Protein mago nashi homolog 2.39
Q6AYD6 PDZ and LIM domain protein 2 2.37
Q4AEF8 Coatomer subunit gamma 2.37
P52481 Adenylyl cyclase-associated protein 2 2.37
P49138 MAP kinase-activated protein kinase 2 2.36
Q99P96 Histone deacetylase 7 2.36
P36372 Antigen peptide transporter 2 2.35
P05811 Alpha-crystallin B chain 2.34
Q5HZV9 Protein phosphatase 1 regulatory subunit 7 2.33
P70615 Lamin-B1 2.32
Q9WUX5 Protein MRVI1 2.32
P16675 Lysosomal protective protein 2.31
Q9EPH8 Polyadenylate-binding protein 1 2.29
Q63560 Microtubule-associated protein 6 2.28
Q60436 Serrate RNA effector molecule homolog (Fragment) 2.26
Q8R081 Heterogeneous nuclear ribonucleoprotein L 2.26
Q561S0 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10,
mitochondrial
2.26
Q5U2R0 Methionine adenosyltransferase 2 subunit beta 2.24
P46664 Adenylosuccinate synthetase isozyme 2 2.21
P0C5W1 Microtubule-associated protein 1S 2.19
Q9WTT6 Guanine deaminase 2.17
O55125 Protein NipSnap homolog 1 2.17
Q6MG49 Large proline-rich protein BAG6 2.16
P04692 Tropomyosin alpha-1 chain 2.16
Q8VC85 U6 snRNA-associated Sm-like protein LSm1 2.16
Q6AYE2 Endophilin-B1 2.16
D3ZU13 Eukaryotic translation initiation factor 4 gamma 1 2.15
Q6MG61 Chloride intracellular channel protein 1 2.14
O55012 Phosphatidylinositol-binding clathrin assembly protein 2.13
Q5U301 A-kinase anchor protein 2 2.13
Q9Z2K1 Keratin, type I cytoskeletal 16 2.13
Q9EPL8 Importin-7 2.10
P14426 H-2 class I histocompatibility antigen, D-K alpha chain 2.06
Q8BSY0 Aspartyl/asparaginyl beta-hydroxylase 2.05
Q6AYQ4 Transmembrane protein 109 2.02
O55096 Dipeptidyl peptidase 3 2.01
P39069 Adenylate kinase isoenzyme 1 (Fragments) 1.98
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The main results of this study is the identification of 250
proteins regulated in cerebral vessels after SAH and the find-
ing that 184 of these proteins returned to sham level or were
contra regulated after treatment with U0126. This underlines
the importance of the MEK/ERK pathway in cerebrovascular
pathology after SAH. The proteins identified in this study
Table 2 (continued)
Accession
number
Protein name Log2
P05982 NAD(P)H dehydrogenase [quinone] 1 1.34
Q9QXQ0 Alpha-actinin-4 1.27
Q62507 Cochlin 1.26
P19132 Ferritin heavy chain 1.20
P38983 40S ribosomal protein SA 1.17
P52944 PDZ and LIM domain protein 1 1.17
P70619 Glutathione reductase (Fragment) 1.14
P24368 Peptidyl-prolyl cis-trans isomerase B 1.12
P38652 Phosphoglucomutase-1 1.07
P63326 40S ribosomal protein S10 1.06
Q5XI28 Ribonucleoprotein PTB-binding 1 1.05
Q9Z1P2 Alpha-actinin-1 1.05
B0BNF1 Septin-8 1.04
P97633 Casein kinase I isoform alpha 1.04
P63102 14-3-3 protein zeta/delta 1.03
Q60972 Histone-binding protein RBBP4 0.99
Q9DB16 Calcium-binding protein 39-like 0.96
Q497B0 Omega-amidase NIT2 0.96
B0BNA7 Eukaryotic translation initiation factor 3 subunit I 0.95
P47853 Biglycan 0.94
Q921M3 Splicing factor 3B subunit 3 0.93
O55126 Protein NipSnap homolog 2 0.93
Q8VHI3 GDP-fucose protein O-fucosyltransferase 2 0.92
P61983 14-3-3 protein gamma 0.91
P28661 Septin-4 0.89
P14046 Alpha-1-inhibitor 3 0.88
P15651 Short-chain specific acyl-CoA dehydrogenase, mitochondrial 0.87
P19804 Nucleoside diphosphate kinase B 0.86
P85972 Vinculin 0.85
P15865 Histone H1.2 0.84
Q58FK9 Kynurenine--oxoglutarate transaminase 3 0.84
P62260 14-3-3 protein epsilon 0.84
Q5XI78 2-Oxoglutarate dehydrogenase, mitochondrial 0.82
B2GV06 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial 0.82
P31977 Ezrin 0.81
Q01129 Decorin 0.80
O88483 [Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 1, mitochondrial 0.80
P18418 Calreticulin 0.80
P12007 Isovaleryl-CoA dehydrogenase, mitochondrial 0.79
O35854 Branched-chain-amino-acid aminotransferase, mitochondrial 0.78
Q66HS7 PDZ and LIM domain protein 3 0.78
P07335 Creatine kinase B-type 0.77
Q9ESW0 DNA damage-binding protein 1 0.77
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comprise strong networks of structural proteins, adaptor pro-
teins, and in addition networks of proteins involved in trans-
lation, mRNA processing, and protein folding.
Remodeling of cerebral arteries is a well-known phenom-
enon to occur after SAH (Edvinsson and Povlsen 2011; Zhang
and Macdonald 2006) and the high number of structural pro-
teins that were observed to be regulated at 2 days after induc-
tion of SAH in this study supports that a structural remodeling
takes place after SAH. Among the structural proteins we ob-
served to be upregulated by SAH was actinin, an important
structural protein in smooth muscle cells. Actinin acts as a
linker between integrins and actin filaments to strengthen the
cytoskeleton and mediate contraction of the smooth muscle
cell (Sun et al. 2008). Another upregulated structural protein is
vinculin, a focal adhesion protein involved in binding
integrins and actin in the cytoskeleton. Vinculin plays a role
in the connection between integrins and actin filaments in the
vasculature (Critchley 2004). The network of structural pro-
teins also included tropomyosin and β-actin, both involved in
contractility of VSMCs.
Table 3 Proteins that show a
SAH-induced downregulation
which does not persist after MEK
inhibition. The list shows proteins
that are downregulated in vehicle-
treated animals (as compared with
sham animals) and either
upregulated or not affected in
U0126-treated animals (as
compared with sham animals).
Regulation is expressed as log2 of
the iTRAQ ratios. This group of
51 proteins is denoted group 2
and represents proteins with an
SAH-induced expressional
decrease that does not persist after
MEK1/2 inhibition
Accession number Protein name Log2
Q64478 Histone H2B type 1-H −4.82
P05811 Alpha-crystallin B chain −4.47
Q8BGD9 Eukaryotic translation initiation factor 4B −4.09
P08009 Glutathione S-transferase Yb-3 −3.64
Q5U2R0 Methionine adenosyltransferase 2 subunit beta −3.39
P62860 40S ribosomal protein S30 −3.29
P23457 3-Alpha-hydroxysteroid dehydrogenase −3.25
Q9Z2G8 Nucleosome assembly protein 1-like 1 −3.14
P55063 Heat shock 70 kDa protein 1-like −3.03
Q8VDM6 Heterogeneous nuclear ribonucleoprotein U-like protein 1 −2.93
P22057 Prostaglandin-H2 D-isomerase −2.87
P04897 Guanine nucleotide-binding protein G(i) subunit alpha-2 −2.76
P27321 Calpastatin −2.76
Q04940 Neurogranin −2.72
O35206 Collagen alpha-1(XV) chain −2.72
Q9CSU0 Regulation of nuclear pre-mRNA domain-containing protein 1B −2.39
Q63362 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 −2.32
Q63768 Adapter molecule crk −2.32
P26043 Radixin −2.23
Q63584 Transmembrane protein Tmp21 −2.20
P27274 CD59 glycoprotein −2.18
Q3T1I4 Protein PRRC1 −2.16
P62142 Serine/threonine-protein phosphatase PP1-beta catalytic subunit −2.15
P55002 Microfibrillar-associated protein 2 −1.39
Q04857 Collagen alpha-1(VI) chain −1.36
P04157 Receptor-type tyrosine-protein phosphatase C −1.22
P11240 Cytochrome c oxidase subunit 5A, mitochondrial −1.22
P15508 Spectrin beta chain, erythrocyte −1.20
P31399 ATP synthase subunit d, mitochondrial −1.15
Q62737 Cytochrome b-245 light chain −1.10
Q02788 Collagen alpha-2(VI) chain −1.09
P26051 CD44 antigen −1.08
Q8BUR4 Dedicator of cytokinesis protein 1 −1.06
P11662 NADH-ubiquinone oxidoreductase chain 2 −1.03
P24623 Alpha-crystallin A chain −1.03
P61805 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 −0.95
P97700 Mitochondrial 2-oxoglutarate/malate carrier protein −0.90
Q9JM51 Prostaglandin E synthase −0.88
Q6AXX6 UPF0765 protein C10orf58 homolog −0.87
P26151 High affinity immunoglobulin gamma Fc receptor I −0.86
Q9R233 Tapasin −0.85
Q9CQ91 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 −0.84
P29419 ATP synthase subunit e, mitochondrial −0.83
Q3B8Q1 Nucleolar RNA helicase 2 −0.83
P06687 Sodium/potassium-transporting ATPase subunit alpha-3 −0.80
P97544 Lipid phosphate phosphohydrolase 3 −0.79
P00697 Lysozyme C-1 −0.77
P11247 Myeloperoxidase −0.77
P08050 Gap junction alpha-1 protein −0.77
Q99P82 Claudin-11 −0.77
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Interestingly, the network analysis in addition highlighted
the 14-3-3 protein family, whose members previously have
been shown to affect the ability of VSMCs to undergo pheno-
typic switch in vitro (Chen et al. 2013). The 14-3-3 proteins
are a family of conserved regulatory molecules that are
expressed in all eukaryotic cells, and we validated their pres-
ence in cerebral arteries by Western blot. The 14-3-3 proteins
have the ability to bind a multitude of functionally diverse
signaling proteins, including kinases, phosphatases, and trans-
membrane receptors. More than 50 signaling proteins have
been reported as 14-3-3 ligands including proteins of the
Ras/Raf/MEK/ERK pathway (Fischer et al. 2009; Fu et al.
2000).
Upregulation of proteins involved in the protein synthesis
pathways of the VSMCs is in line with the fact that in addition
to the structural proteins previously mentioned, several pro-
teins such as receptors, cytokines, and ion channels have been
observed to be upregulated (Edvinsson and Povlsen 2011;
Kamp et al. 2012; Maddahi et al. 2012). Their upregulation
might depend severely on a more efficient protein synthesis
and thereby an upregulation of the protein synthesis pathways.
However, neither the receptors nor the Ca2+ channels were
identified as regulated in this study, but this might very well
be explained by their relatively low abundance compared to,
e.g., structural proteins.
The downregulation of mitochondrial proteins is difficult
to explain. It seems like a paradox that energy-consuming
processes such as protein synthesis are upregulated, while
energy-generating pathways are downregulated. However,
we speculate that the downregulation is not beneficial since
it is abolished after treatment with MEK inhibition, which
according to our findings is beneficial after SAH (Fig. 1).
We show that targeting the MEK-ERK1/2 pathway im-
proves outcome of animals and normalizes protein changes
48 h after SAH. Previous work on SAH have focused on
limited targets, e.g., single receptors, cytokines, or matrix me-
talloproteinases (Ansar et al. 2007; Maddahi et al. 2012;Wang
et al. 2012); however, our approach made it possible to draw a
Fig. 4 Proteins upregulated after experimental SAH and affected by
U0126 treatment (group 1 proteins). Proteins whose upregulation in
large cerebral arteries of rats 48 h after SAH did not persist after U0126
treatment were subjected to network analysis performed with STRING
(www.string.db) software. The network consists of roughly six clusters,
the most predominant containing structural proteins
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global picture of multiple changes. One example of the Bsingle
target^ approach is the Clazosentan trial project (an endothelin
receptor antagonist). By targeting the endothelin receptors
with a specific antagonist Clazosentan, the arterial narrowing
of the vessels was reduced, but it did not improve outcome
after SAH (Macdonald et al. 2012). Therefore it seems that
additional processes play a role in the vascular pathology after
SAH and a total quantitative proteome is a promising tool to
get a broader view of the events that follow SAH.
In summary, the overall findings of this study suggest that
the changes in structural properties of VSMC change after
SAH in a very complex way. These changes can be reduced
by treatment with U0126 and this reduction is associated with
improved neurological outcome. This suggests that MEK1/2
inhibition after SAHmight be a possible treatment strategy for
SAH patients. Moreover, the data from this study comprise a
large dataset that could be very useful for further investiga-
tions and validation of other pathways involved in the com-
plex aftermath of SAH with or without treatment with U0126.
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